However, an important feature of alemtuzumab‐associated Graves’ disease is that it often fluctuates from hyperthyroidism to hypothyroidism and vice versa, in relation to the prevailing activities of stimulatory and blocking TSHR‐Ab [170]. Here, TSHR is linked to hypothyroidism.